Recent regulatory advancements fuel treatment options in oncology and rare diseases. Eli Lilly’s oral selective estrogen receptor degrader imlunestrant received FDA approval for late-stage, ESR1-mutated breast cancer. Crinetics’ Palsonify marks a first-line oral option in acromegaly management. Additionally, advances in radiation oncology present refined imaging and targeted therapies for prostate cancer, with institutions like UCLA and University of Cincinnati showcasing cutting-edge findings at ASTRO 2025. These developments underscore momentum toward precision and patient-friendly therapeutics.